肝切除术作为Bismuth Ⅳ型肝门部胆管癌根治性切除术首选方法的探索

王学文; 李晗; 吴燕彬; 牛洪凯; 孔令群; 成雨

doi:10.3969/j.issn.1001-5256.2020.09.030

肝切除术作为Bismuth Ⅳ型肝门部胆管癌根治性切除术首选方法的探索

DOI: 10.3969/j.issn.1001-5256.2020.09.030

滨州医学院附属医院肝胆外科

基金项目:

山东省普外科临床重点专科建设基金资助项目(ZDZK2013SJ09)；山东省自然基金资助项目(ZR2014HP028)；滨州医学院科研启动基金(BY2015KYQD21)；

详细信息

中图分类号: R735.8
计量
- 文章访问数: 1046
- HTML全文浏览量: 11
- PDF下载量: 98
- 被引次数: 0
出版历程
- 出版日期: 2020-09-20

Hepatectomy as the preferred approach for radical resection of Bismuth Ⅳ hilar cholangiocarcinoma

Department of Hepatobiliary Surgery, Binzhou Medical University Hospital

Research funding:

摘要

摘要:
<正>肝门部胆管癌（hilarcholangiocarcinoma,HCCA）是在肝总管分叉处由胆管上皮引起的恶性肿瘤,占所有胆管癌的50%～60%[1-2]。目前,国内外唯一被公认的临床方法是根治性手术切除[3-4]。BismuthⅣ型被定义为肿瘤累及左右两侧肝管,长期以来被认为是无法手术根治性切除的肿瘤[5]。但在过去的几十年中,随着医疗技术的发展,手术切除被认为是BismuthⅣ型胆管癌治疗的主要方式[6-7],但具体的手术方式尚未达成共识。本研究将肝切除术作为BismuthⅣ型胆管癌根治性切除的
- Klatskin肿瘤 /
- 肝切除术 /
- 治疗学
- Klatskin tumor /
- hepatectomy /
- therapeutics

HTML全文

参考文献(30)

[1] LEWIS HL,RAHNEMAI-AZAR AA,DILLHOFF M,et al. Current Management of Perihilar Cholangiocarcinoma and Future Perspectives[J]. Chirurgia(Bucur),2017,112(3):193-207.

[2] XIONG J,NUNES QM,HUANG W,et al. Major hepatectomy in Bismuth types I and II hilarcholangiocarcinoma[J]. Surg Res,2015,194(1):194-201.

[3] FURUSAWA N,KOBAYASHI A,YOKOYAMA T,et al. Surgical treatment of 144 cases of hilarcholangiocarcinoma without liverrelated mortality[J]. World J Surg,2014,38(5):1164-1176.

[4] JI GW,ZHU FP,WANG K,et al. Clinical implications of biliary confluence pattern for bismuth-corlette typeⅣhilar cholangiocarcinoma applied to hemihepatectomy[J]. J Gastrointest Surg,2017,21(4):666-675.

[5] CROOME KP,ROSEN CB,HEIMBACH JK,et al. Is liver transplantation appropriate for patients with potentially resectable de novo hilarcholangiocarcinoma?[J]. J Am Coll Surg,2015,221(1):130-139.

[6] GOVIL S,REDDY MS,RELA M. Surgical resection techniques for locally advanced hilarcholangiocarcinoma[J]. Langenbecks Arch Surg,2014,399(6):707-716.

[7] XIANG S,LAU WY,CHEN XP. Hilarcholangiocarcinoma:Controversies on the extent of surgical resection aiming at cure[J]. Int J Colorectal Dis,2015,30(2):159-171.

[8] CHEN W,KE K,CHEN YL. Combined portal vein resection in the treatment of hilarcholangiocarcinoma:A systematic review and meta-analysis[J]. Eur J Surg Oncol,2014,40(5):489-495.

[9] BLECHACZ B. Cholangiocarcinoma:Current knowledge and new developments[J]. Gut Liver,2017,11(1):13-26.

[10] KIMBROUGH CW,CLOYD JM,PAWLIK TM. Surgical approaches for the treatment of perihilarcholangiocarcinoma[J]. Expert Rev Anticancer Ther,2018,18(7):673-683.

[11] KU D,TANG R,PANG T,et al. Survival outcomes of hepatic resections in Bismuth-Corlette type IV cholangiocarcinoma[J]. ANZ J Surg,2019.[Online ahead of print]

[12] LI XC,FENG QC. Advance and controversy of hilarcholangiocarcinoma[J]. J Clin Hepatol,2019,35(12):2632-2637.(in Chinese)李相成，冯勤超．肝门部胆管癌的进展与争议[J]．临床肝胆病杂志，2019,35(12):2632-2637.

[13] JOO I,LEE JM,YOON JH. Imaging diagnosis of intrahepatic and perihilarcholangiocarcinoma:Recent advances and challenges[J]. Radiology,2018,288(1):7-13.

[14] LEE HY,KIM SH,LEE JM,et al. Preoperative assessment of resectability of hepatic hilarcholangiocarcinoma:Combined CT and cholangiography with revised criteria[J]. Radiology,2006,239(1):113-121.

[15] TANG Z,YANG Y,MENG W,et al. Best option for preoperative biliary drainage in Klatskin tumor:A systematic review and meta-analysis[J]. Medicine(Baltimore),2017,96(43):e8372.

[16] HUANG ZQ. Change in the opinion of surgical treatment strategy of hepartic portal cholangiocarcinoma[J]. J Clin Surg,2008,16(1):3-4.(in Chinese)黄志强．肝门部胆管癌外科治疗观念能否有所转变[J]．临床外科杂志，2008,16(1):3-4.

[17] RIBERO D,ZIMMITTI G,ALOIA TA,et al. Preoperative cholangitis and future liver remnant volume determine the risk of liver failure in patients undergoing resection for hilarcholangiocarcinoma[J]. J Am Coll Surg,2016,223(1):87-97.

[18] DONG JH,ZHENG SS,CHEN XP,et al. Consensus on evaluation of hepatic functionalreserve before hepatectomy(2011 edition)[J]. Chin J Dig Surg,2011,10(1):20-25.(in Chinese)董家鸿，郑树森，陈孝平，等．肝切除术前肝脏储备功能评估的专家共识(2011版)[J]．中华消化外科杂志，2011,10(1):20-25.

[19] GLANTZOUNIS GK,TOKIDIS E,BASOURAKOS SP,et al.The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review[J]. Eur J SurgOncol,2017,43(1):32-41.

[20] HUA CC,LIU Y,YIN QH. The study of accurate liver volume measurement byIQQA-liver auto analysis software[J]. CT Theory Appl,2019,28(2):229-236.(in Chinese)华晨辰，刘垚，尹其华．IQQA-liver自动分析软件在肝脏体积精确测量方面的应用研究[J]. CT理论与应用研究，2019,28(2):229-236.

[21] AOBA T,EBATA T,YOKOYAMA Y,et al. Assessment of nodal status for perihilarcholangiocarcinoma:Location,number,or ratio of involved nodes[J]. Ann Surg,2013,257(4):718-725.

[22] WANG Y,YANG H,SHEN C,et al. Surgical procedure and long-term survival of hilarcholangiocarcinoma[J]. Int J Clin Exp Med,2015,8(1):1122-1128.

[23] LU Z,WANG DD. Operation treatment method of BismuthCorletteⅢ，Ⅳhilarcholangiocarcinoma[J]. Chin J Surg,2016,54(7):488-491.(in Chinese)鲁正，王冬冬．Bismuth-CorletteⅢ、Ⅳ型肝门部胆管癌的手术治疗方式[J]．中华外科杂志，2016,54(7):488-491.

[24] HONG SS,HAN DH,CHOI GH,et al. Comparison study for surgical outcomes of right versus left side hemihepatectomy to treat hilarcholangiocellular carcinoma[J]. Ann Surg Treat Res,2020,98(1):15-22.

[25] KOW AWC,WOOK CD,SONG SC,et al. Role of caudate lobectomy in type III A and III B hilarcholangiocarcinoma:A 15-year experience in a tertiary institution[J]. World J Surg,2012,36(5):1112-1121.

[26] GAZZANIGA GM,FILAURO M,BAGAROLO C,et al. Surgery for hilarcholangiocarcinoma:An Italian experience[J]. J Hepatobiliary Pancreat Surg,2000,7(2):122-127.

[27] LU CD,HUANG J,WU SD,et al. Total hilar en bloc resection with left hemihepatectomy and caudate lobectomy:A novel approach for treatment of left-sided perihilarcholangiocarcinoma(with video)[J]. J Gastrointest Surg,2017,21(11):1906-1914.

[28] SCHIMIZZI GV,JIN LX,DAVIDSON JT,et al. Outcomes after vascular resection during curative-intent resection for hilarcholangiocarcinoma:A multi-institution study from the US extrahepatic biliary malignancy consortium[J]. HPB(Oxford),2018,20(4):332-339.

[29] MATSUYAMA R,MORI R,OTA Y,et al. Significance of vascular resection and reconstruction in surgery for hilarcholangiocarcinoma:With special reference to hepatic arterial resection and reconstruction[J]. Ann Surg Oncol,2016,23(Suppl 4):475-484.

[30] LIU QH,WANG L,CHU YK,et al. Diagnosis and treatment of surgical resection for 87 cases of hilarcholangiocarcinoma[J].Chin J Gastroenterol Hepatol,2018,27(7):804-807.(in Chinese)刘清华，汪凌，褚延魁，等．87例肝门部胆管癌手术切除的诊疗分析[J]．胃肠病学和肝病学杂志，2018,27(7):804-807.

施引文献

资源附件(0)

访问统计